Rinvoq OverviewUpadacitinib (trade name Rinvoq; code name ABT-494) is a drug for treatment of rheumatoid arthritis. Approved by U.S FDA on 16 August 2019. It was developed by the biotech company AbbVie. Contents 1 Mechanism of action 2 Clinical trials 2.1 Phase I studies 2.2 Phase II studies 2.2.1 BALANCE I 2.2.2 BALANCE II 2.2.3 CELEST 2.3 Phase III studies 3 See also 4 References Mechanism of action The Janus kinases (JAKs) are a family of cytoplasmic tyrosine kinases who...
Read more Rinvoq Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Upadacitinib
Recent Rinvoq Forums:Be the first to start a discussion about this drug.
Possible Dosages for this and Related Drugs:
- Tablet, Extended Release: 15mg
NDC Database Records for Rinvoq: (1 result)Sorted by National Drug Code
- 0074-2306 Rinvoq 15 mg Oral Tablet, Extended Release by Abbvie Inc.